413 related articles for article (PubMed ID: 26254896)
1. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
2. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
6. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
7. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
8. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical localization of RANK, RANKL and OPG in healthy and arthritic canine elbow joints.
Spahni AI; Schawalder P; Rothen B; Bosshardt DD; Lang N; Stoffel MH
Vet Surg; 2009 Aug; 38(6):780-6. PubMed ID: 19674422
[TBL] [Abstract][Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats.
Barger AM; Fan TM; de Lorimier LP; Sprandel IT; O'Dell-Anderson K
J Vet Intern Med; 2007; 21(1):133-40. PubMed ID: 17338161
[TBL] [Abstract][Full Text] [Related]
11. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
12. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
13. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
14. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
16. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
17. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
18. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
19. Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration.
Sano T; Akeda K; Yamada J; Takegami N; Sudo T; Sudo A
BMC Musculoskelet Disord; 2019 May; 20(1):225. PubMed ID: 31101043
[TBL] [Abstract][Full Text] [Related]
20. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.
Mori K; Le Goff B; Berreur M; Riet A; Moreau A; Blanchard F; Chevalier C; Guisle-Marsollier I; Léger J; Guicheux J; Masson M; Gouin F; Rédini F; Heymann D
J Pathol; 2007 Apr; 211(5):555-562. PubMed ID: 17323424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
